Clinical trial · no report yet · Phase 2
CASSIOPEIA
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
- NCT03876769 ↗
- Active, not recruiting
- Novartis Pharmaceuticals
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 135 | |
| YouTube | 86 | |
| Podcasts | 52 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- B-Cell Acute Lymphoblastic Leukemia
- Interventions
- CTL019
- Arms
- Single dose of CTL019 · Experimental
- Enrollment
- 121
- Primary outcomes
- Disease Free Survival (DFS) rate without censoring for new anticancer therapy, including Stem Cell Transplantation (SCT) while in remission
- Overall Survival (OS) rate
- Sponsor
- Novartis Pharmaceuticals with Children's Oncology Group
- Start
- Jun 24, 2019
- Primary completion
- Oct 19, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03876769 · updated Aug 19, 2026
Publications
linked from the registry- Davis KL, Yao CC, Zimmerman JAO, Rau RE. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 Dec;23(12):e257067. doi: 10.6004/jnccn.2025.7067. PubMed 41671463
- Seftel MD. Hyper-CVAD: a regimen for all seasons. Lancet Haematol. 2020 Jul;7(7):e501-e502. doi: 10.1016/S2352-3026(20)30179-4. No abstract available. PubMed 32589970